Dragana Lovre, MD

Associate Professor of Medicine

Phone
(504) 988-9928
School of Medicine
Department
Endocrinology Metabolism & Diabetes
Dragana Lovre, MD

Biography

Dragana Lovre, MD is an Associate Professor of Medicine in the section of Endocrinology at Tulane University SOM. She is also the Associate Program Director for the Endocrinology, Diabetes, and Metabolism Fellowship at Tulane.  Dr. Lovre joined the Section of Endocrinology at Tulane University School of Medicine after completing her Endocrinology Fellowship at Tulane University. Dr. Lovre is board certified in Internal Medicine and Endocrinology. Her clinical and research interests focus on cardiovascular complications of diabetes with special interest women’s health, sex differences and the effect of sex hormones on glucose and lipid metabolism.  In the last few years Dr. Lovre also has been involved in research on sex difference in COVID-19. Dr. Lovre is involved in multiple committees at Tulane and has regional and national presence at endocrinology related societies including the Southern Society of Endocrinologists (SSE), the North American Menopause Society (NAMS), Endocrine Society, and the Association of Program Directors in Endocrinology, Diabetes and Metabolism (APDEM).

 In addition, Dr. Lovre plays a significant role as an educator, she provides lectures and mentoring for medical students, residents and fellows at Tulane University. She also regularly provides endocrinology consultations on the inpatient service.

Contributions

Selected publications

  1. Sex differences in determinants of COVID-19 severe outcomes - findings from the National COVID Cohort Collaborative (N3C).
    Yoshida Y, Chu S, Fox S, Zu Y, Lovre D, Denson JL, Miele L, Mauvais-Jarvis F.BMC Infect Dis. 2022 Oct 12;22(1):784. doi: 10.1186/s12879-022-07776-7.PMID: 36224551 Free PMC article.
     
  2. Acute estradiol and progesterone therapy in hospitalised adults to reduce COVID-19 severity: a randomised control trial.
    Lovre D, Bateman K, Sherman M, Fonseca VA, Lefante J, Mauvais-Jarvis F.BMJ Open. 2021 Nov 30;11(11):e053684. doi: 10.1136/bmjopen-2021-053684.PMID: 34848523 Free PMC article. Clinical Trial.
     
  3. Clinical characteristics and outcomes in women and men hospitalized for coronavirus disease 2019 in New Orleans.
    Yoshida Y, Gillet SA, Brown MI, Zu Y, Wilson SM, Ahmed SJ, Tirumalasetty S, Lovre D, Krousel-Wood M, Denson JL, Mauvais-Jarvis F.Biol Sex Differ. 2021 Feb 5;12(1):20. doi: 10.1186/s13293-021-00359-2.PMID: 33546750 Free PMC article.
     
  4. Effect of conjugated estrogens and bazedoxifene on glucose, energy and lipid metabolism in obese postmenopausal women.
    Marlatt KL, Lovre D, Beyl RA, Tate CR, Hayes EK, Burant CF, Ravussin E, Mauvais-Jarvis F.Eur J Endocrinol. 2020 Oct;183(4):439-452. doi: 10.1530/EJE-20-0619.PMID: 32698159 Free PMC article. Clinical Trial.
     
  5. Conjugated Estrogens and Bazedoxifene Improve β Cell Function in Obese Menopausal Women.
    Lovre D, Peacock E, Katalenich B, Moreau C, Xu B, Tate C, Utzschneider KM, Gautier JF, Fonseca V, Mauvais-Jarvis F.J Endocr Soc. 2019 Jun 6;3(8):1583-1594. doi: 10.1210/js.2019-00074. eCollection 2019 Aug 1.PMID: 31384719 Free PMC article.
     
  6. Managing Diabetes and Cardiovascular Risk in Chronic Kidney Disease Patients.
    Lovre D, Shah S, Sihota A, Fonseca VA.Endocrinol Metab Clin North Am. 2018 Mar;47(1):237-257. doi: 10.1016/j.ecl.2017.10.006. Epub 2017 Dec 18.PMID: 29407054 Free PMC article. Review.
     
  7. The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights.
    Xu B, Lovre D, Mauvais-Jarvis F.J Diabetes Complications. 2017 Apr;31(4):773-779. doi: 10.1016/j.jdiacomp.2016.12.010. Epub 2017 Jan 20.PMID: 28185712 Free PMC article. Review.
     
  8. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?
    Lovre D, Htun W, Carrion C, Fonseca VA.Curr Diab Rep. 2016 Oct;16(10):94. doi: 10.1007/s11892-016-0788-5.PMID: 27541296 Review.
     
  9. Effect of menopausal hormone therapy on components of the metabolic syndrome.
    Lovre D, Lindsey SH, Mauvais-Jarvis F.Ther Adv Cardiovasc Dis. 2016 May 27;11(1):33-43. doi: 10.1177/1753944716649358. Online ahead of print.PMID: 27234158 Free PMC article. Review.
     
  10. Effect of selective estrogen receptor modulators on metabolic homeostasis.
    Xu B, Lovre D, Mauvais-Jarvis F.Biochimie. 2016 May;124:92-97. doi: 10.1016/j.biochi.2015.06.018. Epub 2015 Jun 29.PMID: 26133657 Review.

Full list of publications in PubMed